Once U.S. stockpiles of COVID-19 vaccine run out, Moderna says it might charge as much as $130 per dose, but give people who lack health insurance a break. Critics say that's not enough help.
The Food and Drug Administration has new tools to hold drug companies accountable for promises they make about medications. But the agency has yet to show its hand in using this new power.
The giant retailer shipped billions of opioid pills to pharmacies nationwide. An NPR investigation found employees warned company executives their stores were being used by "pill mill" doctors.
Thousands of lawsuits that ground to a halt because of COVID-19 are moving forward again as local, state and federal courts reopen around the U.S.
The first gene therapy for hemophilia could be approved by the FDA within six months, according to the drugmaker, raising hopes among families. But the drug's price could be $3 million per patient.
Drugs to treat multiple sclerosis can run $70,000 a year or more. Patients hoped competition from a generic version of one of the most popular brands would spur relief, but prices went up. Here's why.
As congressional lawmakers continue to turn up the heat on drugmakers, insurers and middlemen over the price of many medicines, one player says it will limit patients' share of the cost of insulin.
The Trump administration wants to increase transparency in prescription drug pricing. But health economists say the administration's call to tie prices to what other nations pay might work better.
A new poll by the Kaiser Family Foundation shows that many people struggle to pay for medicines and that a majority of Americans would welcome a range of government interventions to lower prices.
Biologic drugs, often made with the help of living organisms, are especially lucrative because they have scant competition from biosimilars, drugs akin to generics. It's a different story in Europe.